UK markets closed
  • NIKKEI 225

    26,748.14
    -253.38 (-0.94%)
     
  • HANG SENG

    20,112.10
    -357.96 (-1.75%)
     
  • CRUDE OIL

    110.44
    +0.67 (+0.61%)
     
  • GOLD FUTURES

    1,864.70
    -0.70 (-0.04%)
     
  • DOW

    31,928.62
    +48.38 (+0.15%)
     
  • BTC-GBP

    23,602.82
    +166.20 (+0.71%)
     
  • CMC Crypto 200

    655.31
    -0.52 (-0.08%)
     
  • ^IXIC

    11,264.45
    -270.83 (-2.35%)
     
  • ^FTAS

    4,126.79
    -23.49 (-0.57%)
     

Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Fresenius Medical Care AG & Co. FMS recently announced that it is launching a new dialyzer for hemodialysis, the FX CorAL— the newest dialyzer in the company’s FX class of dialyzers which use polysulfone (a special plastic with exceptional filtering and hemocompatibility characteristics). The FX CorAL was unveiled in Fresenius Medical Care’s NephroCare clinics after it received the CE mark, and has already been used in more than three million treatments.

For investors’ note, the FX CorAL is already available in Switzerland and will be gradually launched in Germany, France, Italy and the United Arab Emirates. Other countries in the company’s Europe, Middle East and Africa region will follow.

The latest launch is expected to significantly solidify Fresenius Medical’s business on a global scale.

Significance of the Launch

The highlight of the FX CorAL dialyzer is its clinical performance and hemocompatibility. It is noteworthy to mention that dialysis patients often suffer from chronic inflammation caused by the accumulation of toxic substances and the regular contact of their blood with external substances. These inflammations reduce patients’ quality of life and lead to the onset of cardiovascular diseases.

The design of the FX CorAL dialyzer is such that it absorbs lower proteins, thereby achieving a lower induction of the immune response in the patient while maintaining high selective permeability for the removal of toxins and excess water. Additionally, all FX-class dialyzers are steam-sterilized and environment friendly.

Per management, combining clinical performance with hemocompatibility is expected to significantly improve treatment quality of the company’s dialysis patients, thereby enhancing the patients’ well-being.

Industry Prospects

Per a report published by Market Reports World, the global dialyzer market was valued at $6535 million in 2020 and is expected to reach $10210 million by the end of 2027 at a CAGR of 6.6%. Factors like rise in elderly population and surge in incidence of renal diseases (especially end stage renal disease) are likely to drive the market.

Given the market potential, the latest launch is expected to significantly boost Fresenius Medical’s business on a global scale.

Notable Development

In November, Fresenius Medical announced its third-quarter 2021 financial results, where it registered revenue growth across EMEA, Asia Pacific and Latin America regions.

Price Performance

Shares of the company have lost 29.2% in the past year against the industry’s 8.2% rise and the S&P 500 composite’s 27.6% growth.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Zacks Rank & Stocks to Consider

Currently, Fresenius Medical carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation ABC, Thermo Fisher Scientific Inc. TMO and AMN Healthcare Services AMN.

AmerisourceBergen, carrying a Zacks Rank #2 (Buy), reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.39, which beat the Zacks Consensus Estimate by 1.3%. Revenues of $58.91 billion outpaced the consensus mark by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AmerisourceBergen has an estimated long-term growth rate of 11.3%. The company surpassed estimates in the trailing four quarters, the average surprise being 5.48%.

Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.

Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.

AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.

AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report

Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report

AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting